FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3040992225> ?p ?o ?g. }

• W3040992225 endingPage "2488" @default.
• W3040992225 startingPage "2476" @default.
• W3040992225 abstract "Abstract Background & Aims Sorafenib and lenvatinib are the first‐line treatments approved in hepatocellular carcinoma (HCC), but information is lacking about the relationships between their pharmacokinetics, patients pharmacogenetic profiles, adverse events (AE) and overall survival. We aimed to elucidate these relationships of tyrosine Kinase Inhibitors, such as sorafenib, in order to improve the design of trials testing it in combination with checkpoint inhibitors. Methods We assessed the pharmacokinetics of sorafenib and its N‐oxide metabolite at day‐0, day‐7, day‐30, day‐60, day‐90, day‐120, day‐150 and day‐180 and nine single‐nucleotide polymorphisms (SNP) in five genes related to sorafenib metabolism/transport to identify the best point for starting the combination between tyrosine kinases and checkpoint inhibitors. Results We prospectively included 49 patients (96% cirrhotic, 37% hepatitis‐C, 82% Child‐Pugh‐A and 59% BCLC‐C). Pharmacokinetic values peaked at day‐7 and progressively declined until day‐60. In the 16 patients without further dose modifications after day‐60, pharmacokinetic values remained stable through day‐180 (sorafenib P = .90; N‐oxide P = .93). Pharmacokinetic values were higher in patients with early dermatological adverse events and lower in patients with early diarrhoea. Sorafenib and N‐oxide pharmacokinetic values varied linearly with different alleles of MRP2*3972 . Conclusions Sorafenib's pharmacokinetics is heterogeneous across HCC patients. This heterogeneity affects adverse events development and must be taken into account in setting the dose and timing of its combination with checkpoint inhibitors." @default.
• W3040992225 created "2020-07-16" @default.
• W3040992225 creator A5004046885 @default.
• W3040992225 creator A5004565281 @default.
• W3040992225 creator A5014511134 @default.
• W3040992225 creator A5016050250 @default.
• W3040992225 creator A5023182493 @default.
• W3040992225 creator A5025241526 @default.
• W3040992225 creator A5027396370 @default.
• W3040992225 creator A5032069891 @default.
• W3040992225 creator A5036193424 @default.
• W3040992225 creator A5036257020 @default.
• W3040992225 creator A5048453616 @default.
• W3040992225 creator A5053285240 @default.
• W3040992225 creator A5053309637 @default.
• W3040992225 creator A5067464504 @default.
• W3040992225 creator A5079217523 @default.
• W3040992225 creator A5080019152 @default.
• W3040992225 creator A5080639399 @default.
• W3040992225 creator A5090708450 @default.
• W3040992225 date "2020-07-25" @default.
• W3040992225 modified "2023-10-18" @default.
• W3040992225 title "Pharmacokinetics and pharmacogenetics of sorafenib in patients with hepatocellular carcinoma: Implications for combination trials" @default.
• W3040992225 cites W1487455823 @default.
• W3040992225 cites W1964991674 @default.
• W3040992225 cites W1971837077 @default.
• W3040992225 cites W1980241157 @default.
• W3040992225 cites W1995690008 @default.
• W3040992225 cites W2019607817 @default.
• W3040992225 cites W2030379010 @default.
• W3040992225 cites W2079358014 @default.
• W3040992225 cites W2097955112 @default.
• W3040992225 cites W2101270301 @default.
• W3040992225 cites W2116177733 @default.
• W3040992225 cites W2147508125 @default.
• W3040992225 cites W2163403599 @default.
• W3040992225 cites W2168742889 @default.
• W3040992225 cites W2325833357 @default.
• W3040992225 cites W2560499218 @default.
• W3040992225 cites W2787358630 @default.
• W3040992225 cites W2794419219 @default.
• W3040992225 cites W2808732167 @default.
• W3040992225 cites W2898267386 @default.
• W3040992225 cites W2913833678 @default.
• W3040992225 cites W2914775288 @default.
• W3040992225 cites W3000479870 @default.
• W3040992225 cites W3014379579 @default.
• W3040992225 cites W3025022288 @default.
• W3040992225 doi "https://doi.org/10.1111/liv.14587" @default.
• W3040992225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33021346" @default.
• W3040992225 hasPublicationYear "2020" @default.
• W3040992225 type Work @default.
• W3040992225 sameAs 3040992225 @default.
• W3040992225 citedByCount "6" @default.
• W3040992225 countsByYear W30409922252021 @default.
• W3040992225 countsByYear W30409922252022 @default.
• W3040992225 countsByYear W30409922252023 @default.
• W3040992225 crossrefType "journal-article" @default.
• W3040992225 hasAuthorship W3040992225A5004046885 @default.
• W3040992225 hasAuthorship W3040992225A5004565281 @default.
• W3040992225 hasAuthorship W3040992225A5014511134 @default.
• W3040992225 hasAuthorship W3040992225A5016050250 @default.
• W3040992225 hasAuthorship W3040992225A5023182493 @default.
• W3040992225 hasAuthorship W3040992225A5025241526 @default.
• W3040992225 hasAuthorship W3040992225A5027396370 @default.
• W3040992225 hasAuthorship W3040992225A5032069891 @default.
• W3040992225 hasAuthorship W3040992225A5036193424 @default.
• W3040992225 hasAuthorship W3040992225A5036257020 @default.
• W3040992225 hasAuthorship W3040992225A5048453616 @default.
• W3040992225 hasAuthorship W3040992225A5053285240 @default.
• W3040992225 hasAuthorship W3040992225A5053309637 @default.
• W3040992225 hasAuthorship W3040992225A5067464504 @default.
• W3040992225 hasAuthorship W3040992225A5079217523 @default.
• W3040992225 hasAuthorship W3040992225A5080019152 @default.
• W3040992225 hasAuthorship W3040992225A5080639399 @default.
• W3040992225 hasAuthorship W3040992225A5090708450 @default.
• W3040992225 hasConcept C104317684 @default.
• W3040992225 hasConcept C112705442 @default.
• W3040992225 hasConcept C126322002 @default.
• W3040992225 hasConcept C135763542 @default.
• W3040992225 hasConcept C140840227 @default.
• W3040992225 hasConcept C143998085 @default.
• W3040992225 hasConcept C197934379 @default.
• W3040992225 hasConcept C22979827 @default.
• W3040992225 hasConcept C2776264508 @default.
• W3040992225 hasConcept C2777477808 @default.
• W3040992225 hasConcept C2778019345 @default.
• W3040992225 hasConcept C2778695046 @default.
• W3040992225 hasConcept C526171541 @default.
• W3040992225 hasConcept C55493867 @default.
• W3040992225 hasConcept C55775858 @default.
• W3040992225 hasConcept C62231903 @default.
• W3040992225 hasConcept C71924100 @default.
• W3040992225 hasConcept C86803240 @default.
• W3040992225 hasConcept C98274493 @default.
• W3040992225 hasConceptScore W3040992225C104317684 @default.
• W3040992225 hasConceptScore W3040992225C112705442 @default.
• W3040992225 hasConceptScore W3040992225C126322002 @default.

• next